The European Medicines Agency accepted marketing authorization application for Teva Pharmaceutical Industries Ltd.'s fremanezumab to treat migraine in adults.
Israel-based Teva said the marketing authorization application was based on data from its Halo trial, which enrolled more than 2,000 patients with episodic and chronic migraine.
Teva also filed an application for the medicine with the U.S. Food and Drug Administration in 2017.
